NantHealth (NASDAQ:NH) Earns Coverage Optimism Rating of 0.20

Press coverage about NantHealth (NASDAQ:NH) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. NantHealth earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.4745905080444 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

Shares of NantHealth (NASDAQ NH) traded up $0.05 during trading hours on Wednesday, hitting $3.04. The stock had a trading volume of 61,941 shares, compared to its average volume of 155,617. NantHealth has a 1 year low of $2.60 and a 1 year high of $7.97. The stock has a market capitalization of $320.66, a PE ratio of -1.68 and a beta of 0.21. The company has a debt-to-equity ratio of 0.93, a quick ratio of 2.36 and a current ratio of 2.38.

A number of equities research analysts recently weighed in on NH shares. BidaskClub cut NantHealth from a “hold” rating to a “sell” rating in a research note on Friday, January 26th. Zacks Investment Research upgraded NantHealth from a “hold” rating to a “buy” rating and set a $3.50 price objective for the company in a research note on Thursday, December 21st. Finally, Canaccord Genuity decreased their price target on NantHealth from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Friday, November 17th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $8.05.

COPYRIGHT VIOLATION NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/02/14/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-nanthealth-nh-share-price.html.

NantHealth Company Profile

NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.

Insider Buying and Selling by Quarter for NantHealth (NASDAQ:NH)

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply